The presage® ST2 assay: Analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble ST2

Expert Review of Molecular Diagnostics

Volumn 13, Issue 1, 2013, Pages 13-30

  Mueller, Thomas ^a   Dieplinger, Benjamin ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

acute coronary syndrome; acute myocardial infarction; asthma; B type natriuretic peptide; biomarker; cardiovascular disease; chronic obstructive pulmonary disease; emergency department; heart disease; heart failure; IL 33; ILRL1; inflammation; mortality; natriuretic peptide; outcome; pneumonia; prognosis; sepsis; ST2

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; CHEMOKINE; CYTOKINE; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 33; PROTEIN SST2; TROPONIN T; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ASSAY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CRITICALLY ILL PATIENT; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIAGNOSTIC KIT; DYSPNEA; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSCRIPTION; HEART FAILURE; HEART MUSCLE CELL; HUMAN; INTENSIVE CARE UNIT; INTERMETHOD COMPARISON; KIDNEY DISEASE; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PNEUMONIA; PROGNOSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; STROMA CELL; THORAX PAIN;

BIOLOGICAL MARKERS; HEART FAILURE; HUMANS; INTERLEUKINS; MYOCARDIAL INFARCTION; PROGNOSIS; RECEPTORS, CELL SURFACE; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION;

EID: 84871535752     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.12.128     Document Type: Review

References (89)

1. Weinberg EO. ST2 protein in heart disease: from discovery to mechanisms and prognostic value. Biomark. Med. 3(5), 495-511 (2009).
2. Miller AM, Liew FY. The IL-33/ST2 pathway-a new therapeutic target in cardiovascular disease. Pharmacol. Ther. 131(2), 179-186 (2011).
3. Dieplinger B, Januzzi Jr. JL , Steinmair M et al. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma-the Presage ST2 Assay. Clin. Chim. Acta 409(1-2), 33-40 (2009).
4. Tominaga S. A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett. 258(2), 301-304 (1989).
5. Werenskiold AK, Hoffmann S, Klemenz R. Induction of a mitogen-responsive gene after expression of the Ha-ras oncogene in NIH 3T3 fibroblasts. Mol. Cell. Biol. 9(11), 5207-5214 (1989).
6. Schmitz J, Owyang A, Oldham E et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23(5), 479-490 (2005).
7. Kakkar R, Hei H, Dobner S, Lee RT. Interleukin 33 as a mechanically responsive cytokine secreted by living cells. J. Biol. Chem. 287(9), 6941-6948 (2012).
8. Mildner M, Storka A, Lichtenauer M et al. Primary sources and immunological prerequisites for sST2 secretion in humans. Cardiovasc. Res. 87(4), 769-777 (2010).
9. Weinberg EO, Shimpo M, De Keulenaer GW et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 106(23), 2961-2966 (2002).
10. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J. Clin. Invest. 117(6), 1538-1549 (2007).
11. Seki K, Sanada S, Kudinova AY et al. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ. Heart Fail. 2(6), 684-691 (2009).
12. Kuroiwa K, Li H, Tago K et al. Construction of ELISA system to quantify human ST2 protein in sera of patients. Hybridoma 19(2), 151-159 (2000).
13. Shimpo M, Morrow DA, Weinberg EO et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 109(18), 2186-2190 (2004).
14. Sabatine MS, Morrow DA, Higgins LJ et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 117(15), 1936-1944 (2008).
15. Eggers KM, Armstrong PW, Califf RM et al. ST2 and mortality in non-ST-segment elevation acute coronary syndrome. Am. Heart J. 159(5), 788-794 (2010).
16. Dhillon OS, Narayan HK, Quinn PA, Squire IB, Davies JE, Ng LL. Interleukin 33 and ST2 in non-ST-elevation myocardial infarction: comparison with Global Registry of Acute Coronary Events Risk Scoring and NT-proBNP. Am. Heart J. 161(6), 1163-1170 (2011).
17. Kohli P, Bonaca MP, Kakkar R et al. Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLINTIMI 36 trial. Clin. Chem. 58(1), 257-266 (2012).
18. Weir RA, Miller AM, Murphy GE et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J. Am. Coll. Cardiol. 55(3), 243-250 (2010).
19. Brown AM, Wu AH, Clopton P, Robey JL, Hollander JE. ST2 in emergency department chest pain patients with potential acute coronary syndromes. Ann. Emerg. Med. 50(2), 153-8, 158.e1 (2007).
20. Aldous SJ, Richards AM, Troughton R, Than M. ST2 has diagnostic and prognostic utility for all-cause mortality and heart failure in patients presenting to the emergency department with chest pain. J. Card. Fail. 18(4), 304-310 (2012).
21. Mueller T, Dieplinger B, Gegenhuber A, Poelz W, Pacher R, Haltmayer M. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin. Chem. 54(4), 752-756 (2008).
22. Rehman SU, Mueller T, Januzzi Jr. JL . Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J. Am. Coll. Cardiol. 52(18), 1458-1465 (2008).
23. Manzano-Fernández S, Mueller T, Pascual-Figal D, Truong QA, Januzzi JL. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am. J. Cardiol. 107(2), 259-267 (2011).
24. Pascual-Figal DA, Manzano-Fernández S, Boronat M et al. Soluble ST2, high-sensitivity troponin T-and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur. J. Heart Fail. 13(7), 718-725 (2011).
25. Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 107(5), 721-726 (2003).
26. Pascual-Figal DA, Ordoñez-Llanos J, Tornel PL et al.; MUSIC Investigators. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J. Am. Coll. Cardiol. 54(23), 2174-2179 (2009).
27. Daniels LB, Clopton P, Iqbal N, Tran K, Maisel AS. Association of ST2 levels with cardiac structure and function and mortality in outpatients. Am. Heart J. 160(4), 721-728 (2010).
28. Ky B, French B, McCloskey K et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ. Heart Fail. 4(2), 180-187 (2011).
29. Ky B, French B, Levy WC et al. Multiple biomarkers for risk prediction in chronic heart failure. Circ. Heart Fail. 5(2), 183-190 (2012).
30. Bayes-Genis A, de Antonio M, Galán A et al. Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure. Eur. J. Heart Fail. 14(1), 32-38 (2012).
31. Broch K, Ueland T, Nymo SH et al. Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology. Eur. J. Heart Fail. 14(3), 268-277 (2012).
32. Boisot S, Beede J, Isakson S et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J. Card. Fail. 14(9), 732-738 (2008).
33. Bayes-Genis A, Pascual-Figal D, Januzzi JL et al. Soluble ST2 monitoring provides additional risk stratification for outpatients with decompensated heart failure. Rev. Esp. Cardiol. 63(10), 1171-1178 (2010).
34. Januzzi Jr. JL , Peacock WF, Maisel AS et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J. Am Coll. Cardiol. 50(7), 607-613 (2007).
35. Dieplinger B, Gegenhuber A, Haltmayer M, Mueller T. Evaluation of novel biomarkers for the diagnosis of acute destabilised heart failure in patients with shortness of breath. Heart 95(18), 1508-1513 (2009).
36. Martinez-Rumayor A, Camargo CA, Green SM, Baggish AL, O'Donoghue M, Januzzi JL. Soluble ST2 plasma concentrations predict 1-year mortality in acutely dyspneic emergency department patients with pulmonary disease. Am. J. Clin. Pathol. 130(4), 578-584 (2008).
37. Rehman SU, Martinez-Rumayor A, Mueller T, Januzzi Jr. JL . Independent and incremental prognostic value of multimarker testing in acute dyspnea: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Clin. Chim. Acta 392(1-2), 41-45 (2008).
38. Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR, Januzzi JL. Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. Circ. Heart Fail. 2(4), 311-319 (2009).
39. Dieplinger B, Gegenhuber A, Kaar G, Poelz W, Haltmayer M, Mueller T. Prognostic value of established and novel biomarkers in patients with shortness of breath attending an emergency department. Clin. Biochem. 43(9), 714-719 (2010).
40. Januzzi Jr. JL , Rehman S, Mueller T, van Kimmenade RR, Lloyd-Jones DM. Importance of biomarkers for long-term mortality prediction in acutely dyspneic patients. Clin. Chem. 56(12), 1814-1821 (2010).
41. Socrates T, deFilippi C, Reichlin T et al. Interleukin family member ST2 and mortality in acute dyspnoea. J. Intern. Med. 268(5), 493-500 (2010).
42. Shah KB, Kop WJ, Christenson RH et al. Prognostic utility of ST2 in patients with acute dyspnea and preserved left ventricular ejection fraction. Clin. Chem. 57(6), 874-882 (2011).
43. Dieplinger B, Egger M, Poelz W, Haltmayer M, Mueller T. Long-term stability of soluble ST2 in frozen plasma samples. Clin. Biochem. 43(13-14), 1169-1170 (2010).
44. Lu J, Snider JV, Grenache DG. Establishment of reference intervals for soluble ST2 from a United States population. Clin. Chim. Acta 411(21-22), 1825-1826 (2010).
45. Dieplinger B, Egger M, Poelz W, Gabriel C, Haltmayer M, Mueller T. Soluble ST2 is not independently associated with androgen and estrogen status in healthy males and females. Clin. Chem. Lab. Med. 49(9), 1515-1518 (2011).
46. Mueller T, Zimmermann M, Dieplinger B, Ankersmit HJ, Haltmayer M. Comparison of plasma concentrations of soluble ST2 measured by three different commercially available assays: The MBL ST2 assay, the Presage ST2 Assay, and the R&D ST2 assay. Clin. Chim. Acta 413(19-20), 1493-1494 (2012).
47. Fousteris E, Melidonis A, Panoutsopoulos G et al. Toll/interleukin-1 receptor member ST2 exhibits higher soluble levels in Type 2 diabetes, especially when accompanied with left ventricular diastolic dysfunction. Cardiovasc. Diabetol. 10, 101 (2011).
48. Pascual-Figal DA, Garrido IP, Blanco R et al. Soluble ST2 is a marker for acute cardiac allograft rejection. Ann. Thorac. Surg. 92(6), 2118-2124 (2011).
49. Sato YZ, Molkara DP, Daniels LB et al. Cardiovascular biomarkers in acute Kawasaki disease. Int. J. Cardiol. doi:10.1016/j.ijcard.2011.06.065 (2011) (Epub ahead of print).
50. Granne I, Southcombe JH, Snider JV et al. ST2 and IL-33 in pregnancy and preeclampsia. PLoS One 6(9), e24463 (2011).
51. Dieplinger B, Egger M, Koehler W et al. Prognostic value of soluble ST2 in an unselected cohort of patients admitted to an intensive care unit-the Linz Intensive Care Unit (LICU) study. Clin. Chim. Acta 413(5-6), 587-593 (2012).
52. Sawaya H, Sebag IA, Plana JC et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes and trastuzumab. Circ. Cardiovasc. Imaging 5(5), 596-603 (2012).
53. Apple FS, Steffen LM, Pearce LA, Murakami MM, Luepker RV. Increased cardiac troponin I as measured by a high-sensitivity assay is associated with high odds of cardiovascular death: the Minnesota Heart Survey. Clin. Chem. 58(5), 930-935 (2012).
54. Alves-Filho JC, Sônego F, Souto FO et al. Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nat. Med. 16(6), 708-712 (2010).
55. Brunner M, Krenn C, Roth G et al. Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. Intensive Care Med. 30(7), 1468-1473 (2004).
56. Hoogerwerf JJ, Tanck MW, van Zoelen MA, Wittebole X, Laterre PF, van der Poll T. Soluble ST2 plasma concentrations predict mortality in severe sepsis. Intensive Care Med. 36(4), 630-637 (2010).
57. Wagenaar JF, Gasem MH, Goris MG et al. Soluble ST2 levels are associated with bleeding in patients with severe Leptospirosis. PLoS Negl. Trop. Dis. 3(6), e453 (2009).
58. Becerra A, Warke RV, de Bosch N, Rothman AL, Bosch I. Elevated levels of soluble ST2 protein in dengue virus infected patients. Cytokine 41(2), 114-120 (2008).
59. Oshikawa K, Kuroiwa K, Tago K et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am. J. Respir. Crit. Care Med. 164(2), 277-281 (2001).
60. Ali M, Zhang G, Thomas WR et al. Investigations into the role of ST2 in acute asthma in children. Tissue Antigens 73(3), 206-212 (2009).
61. Tajima S, Oshikawa K, Tominaga S, Sugiyama Y. The increase in serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis. Chest 124(4), 1206-1214 (2003).
62. Hacker S, Lambers C, Pollreisz A et al. Increased soluble serum markers caspase-cleaved cytokeratin-18, histones, and ST2 indicate apoptotic turnover and chronic immune response in COPD. J. Clin. Lab. Anal. 23(6), 372-379 (2009).
63. Oshikawa K, Kuroiwa K, Tokunaga T et al. Acute eosinophilic pneumonia with increased soluble ST2 in serum and bronchoalveolar lavage fluid. Respir. Med. 95(6), 532-533 (2001).
64. Scott PA, Townsend PA, Ng LL et al. Defining potential to benefit from implantable cardioverter defibrillator therapy: the role of biomarkers. Europace 13(10), 1419-1427 (2011).
65. Zhang HF, Xie SL, Cheng YX et al. Altered serum levels of IL-33 in patients with advanced systolic chronic heart failure: correlation with oxidative stress. J. Transl. Med. 10(1), 120 (2012).
66. Porcel JM, Martínez-Alonso M, Cao G, Bielsa S, Sopena A, Esquerda A. Biomarkers of heart failure in pleural fluid. Chest 136(3), 671-677 (2009).
67. Bartunek J, Delrue L, Van Durme F et al. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J. Am. Coll. Cardiol. 52(25), 2166-2174 (2008).
68. Szerafin T, Brunner M, Horváth A et al. Soluble ST2 protein in cardiac surgery: a possible negative feedback loop to prevent uncontrolled inflammatory reactions. Clin. Lab. 51(11-12), 657-663 (2005).
69. Szerafin T, Niederpold T, Mangold A et al. Secretion of soluble ST2-possible explanation for systemic immunosuppression after heart surgery. Thorac. Cardiovasc. Surg. 57(1), 25-29 (2009).
70. Bruneau S, Le Berre L, Hervé C et al. Potential role of soluble ST2 protein in idiopathic nephrotic syndrome recurrence following kidney transplantation. Am. J. Kidney Dis. 54(3), 522-532 (2009).
71. Bao YS, Na SP, Zhang P et al. Characterization of interleukin-33 and soluble ST2 in serum and their association with disease severity in patients with chronic kidney disease. J. Clin. Immunol. 32(3), 587-594 (2012).
72. Roth GA, Zimmermann M, Lubsczyk BA et al. Up-regulation of interleukin 33 and soluble ST2 serum levels in liver failure. J. Surg. Res. 163(2), e79-e83 (2010).
73. Wang J, Cai Y, Ji H et al. Serum IL-33 levels are associated with liver damage in patients with chronic hepatitis B. J. Interferon Cytokine Res. 32(6), 248-253 (2012).
74. Ouziel R, Gustot T, Moreno C et al. The ST2 pathway is involved in acute pancreatitis: a translational study in humans and mice. Am. J. Pathol. 180(6), 2330-2339 (2012).
75. Pastorelli L, Garg RR, Hoang SB et al. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc. Natl Acad. Sci. USA 107(17), 8017-8022 (2010).
76. Díaz-Jiménez D, Núñez LE, Beltrán CJ et al. Soluble ST2: a new and promising activity marker in ulcerative colitis. World J. Gastroenterol. 17(17), 2181-2190 (2011).
77. Beltrán CJ, Núñez LE, Díaz-Jiménez D et al. Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 16(7), 1097-1107 (2010).
78. Shimizu M, Matsuda A, Yanagisawa K et al. Functional SNPs in the distal promoter of the ST2 gene are associated with atopic dermatitis. Hum. Mol. Genet. 14(19), 2919-2927 (2005).
79. Wakatabi K, Komine M, Meephansan J et al. The levels of soluble ST2 in sera and bullous fluid from patients with bullous pemphigoid. Eur. J. Dermatol. 22(3), 333-336 (2012).
80. Talabot-Ayer D, McKee T, Gindre P et al. Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Joint Bone Spine 79(1), 32-37 (2012).
81. Hong YS, Moon SJ, Joo YB et al. Measurement of interleukin-33 (IL-33) and IL-33 receptors (sST2 and ST2L) in patients with rheumatoid arthritis. J. Korean Med. Sci. 26(9), 1132-1139 (2011).
82. Mok MY, Huang FP, Ip WK et al. Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus. Rheumatology (Oxford) 49(3), 520-527 (2010).
83. Kuroiwa K, Arai T, Okazaki H, Minota S, Tominaga S. Identification of human ST2 protein in the sera of patients with autoimmune diseases. Biochem. Biophys. Res. Commun. 284(5), 1104-1108 (2001).
84. Sahlander K, Larsson K, Palmberg L. Increased serum levels of soluble ST2 in birch pollen atopics and individuals working in laboratory animal facilities. J. Occup. Environ. Med. 52(2), 214-218 (2010).
85. Oshikawa K, Yanagisawa K, Ohno S, Tominaga S, Sugiyama Y. Expression of ST2 in helper T lymphocytes of malignant pleural effusions. Am. J. Respir. Crit. Care Med. 165(7), 1005-1009 (2002).
86. Gillibert-Duplantier J, Duthey B, Sisirak V et al. Gene expression profiling identifies sST2 as an effector of ErbB2-driven breast carcinoma cell motility, associated with metastasis. Oncogene 31(30), 3516-3524 (2012).
87. Rechardt M, Shiri R, Matikainen S, Viikari-Juntura E, Karppinen J, Alenius H. Soluble IL-1RII and IL-18 are associated with incipient upper extremity soft tissue disorders. Cytokine 54(2), 149-153 (2011).
88. Kanda M, Ohto-Ozaki H, Kuroiwa K, Tominaga S, Watanabe E, Iwahana H. Elevation of ST2 protein levels in cerebrospinal fluid following subarachnoid hemorrhage. Acta Neurol. Scand. 113(5), 327-333 (2006).
89. Lin CY, Pfluger CM, Henderson RD, McCombe PA. Reduced levels of interleukin 33 and increased levels of soluble ST2 in subjects with amyotrophic lateral sclerosis. J. Neuroimmunol. 249(1-2), 93-95 (2012).